Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease

Abstract

The effect of sodium‐glucose cotransporter 2 inhibitor (SGLT2I) on nonalcoholic steatohepatitis (NASH) has been reported, but there are few studies on its effect on NASH‐related renal injury. In this study, we examined the effect of SGLT2I using a novel medaka fish model of NASH‐related kidney disease, which was developed by feeding the d‐rR/Tokyo strain a high‐fat diet. SGLT2I was administered by dissolving it in water of the feeding tank. SGLT2I ameliorates macrophage accumulation and oxidative stress and maintained mitochondrial function in the kidney. The results demonstrate the effect of SGLT2I on NASH‐related renal injury and the usefulness of this novel animal model for research into NASH‐related complications.

Effect of Luseogliflozin on liver function, BNP and baPWV in diabetics with coronary artery disease

“…The effects of luseogliflozin on BNP and liver function tests agreed with the previous studies 18,19) . The DAPA-HF 20,21) , EMPEROR-Reduced 22,23) , and DEFINE-HF 24) trials showed SGLT2i was effective in reducing HF aggravation risk.…”

Device implant based on poly (lactic acid) with vitamin E for vaccine delivery system in Tilapia: Study for biocompatibility and biodegradation

“…These giant cells participate in the release of pro-inflammatory agents, which favor the recruitment, accumulation, and activation of new macrophages, which act in the degradation and absorption of biomaterials [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] . Phagocytic cells (F4 / 80 +) have been reported in medaka fish used as a model for inflammation and oxidative stress, describing that positive cells are activated macrophages [55] . During this experiment, we did not observe the complete device biodegradation, possibly due to the short analysis period (120 days), since the time required for PLA biodegradation is estimated to be about 2 years [56] .…”

Antioxidant Roles of SGLT2 Inhibitors in the Kidney

“…In addition, among CKD patients participating in the DAPA-CKD clinical trial, those treated with dapagliflozin had better stabilization of GFR and a lower risk of progression to end-stage renal disease or death, again, independent of the presence of diabetes [ 120 ]. Although the renal antioxidant effect of the SGLT2is in nondiabetic human CKD needs to be assessed in future research, studies in nondiabetic experimental models of kidney damage have already shown that these drugs protect the kidney by decreasing oxidative stress [ 121 , 122 ]. Furthermore, SGLT2is also have antioxidant properties in organs other than the kidney.…”